Skip Navigation

A Phase I/II Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04184050

Study #:
STUDY00145416

Start Date:
Aug 13, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04184050

View Complete Trial Details & Eligibility at ClinicalTrials.gov